Skip to main content
    C

    Charles River Laboratories (CRL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $337.97
    +24.95 (+7.97%)

    Market Cap: $15.00B

    Last updated: Nov 06, 2026 at 4:40 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    100%(40/40)
    Avg Surprise
    +9.31%
    Streak
    45 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$3.73
    Range$3.37 - $3.85
    17 analysts
    Revenue Consensus
    $1.0B
    Range$986M - $1.0B
    14 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$3.73$3.37 - $3.85--17--
    Sep 26
    Reported Nov 4
    		$3.09$2.98$2.93 - $3.09+3.69%Beat13
    4
    2
    30d
    		+27.2%
    Jun 26
    Reported Aug 5
    		$3.02$2.72$2.58 - $2.91+11.03%Beat12
    1
    0
    30d
    		-3.2%
    Mar 26
    Reported May 7
    		$2.06$1.95$1.91 - $2.11+5.64%Beat13
    2
    4
    30d
    		-12.0%
    Dec 25
    Reported Feb 18
    		$2.39$2.33$2.25 - $2.44+2.58%Beat14
    2
    1
    30d
    		-10.2%
    Sep 25
    Reported Nov 5
    		$2.43$2.32$2.30 - $2.48+4.74%Beat14
    1
    1
    30d
    		-6.2%
    Jun 25
    Reported Aug 6
    		$3.12$2.55$2.46 - $2.57+22.35%Beat14
    3
    0
    30d
    		+11.4%
    Mar 25
    Reported May 7
    		$2.34$2.07$2.00 - $2.27+13.04%Beat15
    3
    6
    30d
    		+3.1%
    Dec 24
    Reported Feb 19
    		$2.66$2.53$2.45 - $2.64+5.14%Beat16
    0
    5
    30d
    		+8.1%
    Sep 24
    Reported Nov 6
    		$2.59$2.42$2.36 - $2.49+7.02%Beat15
    3
    0
    30d
    		-4.8%
    Jun 24
    Reported Aug 7
    		$2.80$2.39$2.36 - $2.43+17.15%Beat16
    1
    0
    30d
    		+4.1%
    Mar 24
    Reported May 9
    		$2.27$2.06$2.00 - $2.11+10.19%Beat13
    No revisions (30d)
    		-18.3%
    Dec 23
    Reported Feb 14
    		$2.46$2.40$2.25 - $2.48+2.50%Beat13
    No revisions (30d)
    		-17.4%

    Key Metrics

    Valuation
    P/E Ratio32.00EV/EBITDA63.42x
    Price/FCF40.43xFCF Yield2.47%
    Profitability
    Profit Margin1.01%Operating Margin20.60%
    ROE1.27%ROIC0.06%
    Financial Health
    Debt/Equity0.76xInterest Coverage0.05x
    Current Ratio1.41xQuick Ratio1.12x
    Trading Statistics
    Beta1.34Avg Volume1.24M
    52-Week High$379.6352-Week Low$146.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$349.33
    SMA 20$332.40
    SMA 50$305.61
    SMA 200$224.56
    EMA 10$338.48
    EMA 20$332.24
    EMA 50$309.42
    EMA 200$243.80

    MACD

    Line: 10.55Signal: 14.22Hist: -3.67

    ADX

    ADX: 36.3+DI: 25.0-DI: 22.8

    Aroon & PSAR

    Aroon Up76.0
    Aroon DownN/A
    PSAR$375.87

    Bollinger Bands

    Upper Band$384.62
    Lower Band$280.17
    %B Position3142%(Upper)
    Band Width0.55

    RSI (14-Day)

    Neutral
    53.9

    Momentum Oscillators

    Stoch %K33.2
    Stoch %D41.7
    Williams %R-55.1
    ROC (10d)-2.1%
    Momentum-7.40
    CCI (20d)-2.2
    MFI (14d)65.6

    Volatility Measures

    ATR (14d)$17.49(5.2%)
    StdDev (20d)26.11
    Hist Vol68.1%(High)

    Volume Flow

    VWAP$331.47
    OBV31.6M
    AD Line22.3M
    CMF (20d)0.049

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.8x
    VWMA (20d)$336.60

    Pivot Points

    R3$344.36
    R2$337.55
    R1$325.29
    Pivot Point$318.48
    S1$306.22
    S2$299.41
    S3$287.15

    Advanced Oscillators

    TSI17.94
    Ultimate Osc43.0
    KST183.96

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$982.73M$1.00B$995.83M$994.23M$1.00B$1.03B$984.17M$1.00B$1.01B$1.03B$1.01B$1.01B
    Cost of Revenue$624.86M$640.70M$701.17M$684.54M$666.06M$675.07M$666.44M$718.30M$660.74M$672.40M$666.72M$649.39M
    Gross Profit$357.87M$363.37M$294.66M$309.68M$338.79M$357.07M$317.73M$284.24M$349.02M$353.71M$344.84M$364.08M
    Operating Expenses$155.23M$243.49M$174.77M$593.12M$204.99M$256.93M$243.06M$451.93M$231.62M$202.06M$218.87M$231.16M
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$140.59M$228.90M$159.42M$196.14M$177.59M$191.55M$177.80M$195.71M$199.21M$169.79M$186.29M$197.14M
    Operating Income$202.64M$119.89M$119.90M$-283,440,000$133.80M$100.13M$74.67M$-167,687,000$117.41M$151.65M$125.98M$132.92M
    Interest Income$958,000$1.03M$1.03M$1.02M$1.42M$1.10M$1.40M$1.83M$1.53M$3.01M$2.20M$1.59M
    Interest Expense$28.52M$30.34M$26.74M$23.77M$25.40M$29.97M$27.88M$28.23M$30.28M$32.77M$35.00M$33.54M
    Income Before Tax$170.66M$53.17M$-29,942,000$-294,099,000$87.20M$71.42M$35.98M$-216,791,000$91.24M$119.65M$99.01M$208.71M
    Income Tax Expense$-163,787,000$53.93M$-15,140,000$-17,809,000$31.64M$18.73M$10.10M$-3,044,000$20.95M$25.39M$24.53M$19.75M
    Net Income$334.44M$-760,000$-14,802,000$-276,290,000$55.56M$52.69M$25.88M$-213,747,000$70.30M$94.26M$74.48M$188.95M
    EBITDA$270.48M$149.77M$62.92M$-193,064,000$196.34M$219.79M$182.82M$-88,288,000$208.19M$235.49M$217.17M$321.17M
    EBIT$198.22M$82.48M$-4,233,000$-271,341,000$111.18M$100.29M$62.46M$-190,392,000$120.00M$149.41M$131.81M$240.66M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRL

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    59
    New Awards (TTM)
    24
    Avg Remaining Term
    7.6 mo

    Recent Awards

    Award IDAgencyObligatedStart
    75N98025F00011Department of Health and Human ServicesNational Institutes of Health$9.67MAug 12, 2019
    75N98025F00012Department of Health and Human ServicesNational Institutes of Health$8.56MAug 12, 2019
    75N95025F00001Department of Health and Human ServicesNational Institutes of Health$7.18MSep 30, 2025
    75N98026F00002Department of Health and Human ServicesNational Institutes of Health$5.29MMar 1, 2026
    75N93025F00001Department of Health and Human ServicesNational Institutes of Health$5.24MSep 30, 2025
    75N95026F00001Department of Health and Human ServicesNational Institutes of Health$1.92MJan 20, 2026
    75N95025F00001Department of Health and Human ServicesNational Institutes of Health$1.14MSep 30, 2025
    75N98026F00001Department of Health and Human ServicesNational Institutes of Health$935908Mar 1, 2026
    75N98026F00002Department of Health and Human ServicesNational Institutes of Health$339743Jun 15, 2026
    75N98026F00001Department of Health and Human ServicesNational Institutes of Health$339743Jun 15, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Charles River Laboratories International Inc. stock outperforms competitors on strong trading day

    Charles River Laboratories International Inc. (CRL) stock saw a significant increase of 7.83% to $337.52, outperforming the S&P 500 which rose 0.31% and the Dow Jones Industrial Average which fell 0.46%. This rise broke...

    MarketWatch•11/6/26•Bullish

    Danaher (DHR) Won FDA Clearances, Is The Discount Too Cautious?

    Danaher (DHR) has gained renewed investor interest following recent FDA clearances for its Cepheid Xpert Hemorrhagic Fever Panel and Beckman Coulter Access MeMed BV assay...

    Simply Wall St•11/6/26•Neutral

    ICON (ICLR) Launches FIRECREST AI Video Engine For Clinical Trial Communications

    ICON plc (NasdaqGS:ICLR) has launched its FIRECREST AI-Directed Video Engine, an AI-powered tool designed to automate and standardize clinical trial communications for sites and patients. This new platform aims...

    Simply Wall St•11/6/26•Neutral

    Charles River Laboratories International, Inc. Just Beat EPS By 244%: Here's What Analysts Think Will Happen Next

    Charles River Laboratories International (NYSE: CRL) significantly surpassed analyst expectations for its quarterly results...

    Simply Wall St•11/6/26•Somewhat-Bullish

    Charles River Laboratories International Q3 Earnings Call Highlights

    Charles River Laboratories International (CRL) exceeded its Q3 forecasts, with organic revenue up 4.7% and non-GAAP earnings per share rising 27.2% to $3.09...

    TradingView•11/5/26•Bullish

    CRL Valuation and Fair Value

    P/E
    32.0x
    Forward P/E
    26.4x
    EV/EBITDA
    63.4x
    P/FCF
    40.4x
    PEG
    0.1x
    P/B
    5.0x
    See GNG's fair value

    CRL Profitability: Margins, ROIC and FCF

    Gross margin
    33.3%
    Operating margin
    20.6%
    Net margin
    1.0%
    ROIC
    0.1%
    ROE
    1.3%
    FCF margin
    10.0%
    FCF yield
    2.5%

    CRL Competitors

    CompanyTicker
    ICON PLCICLR
    Solventum Corp.SOLV
    Neurocrine Biosciences IncNBIX
    Jazz Pharmaceuticals PLCJAZZ
    Exelixis IncEXEL
    BridgeBio Pharma IncBBIO
    Revvity Inc.RVTY
    Halozyme Therapeutics IncHALO

    Sector: Healthcare

    CRL Analyst Ratings

    Consensus
    Buy
    Analysts
    18
    Strong Buy
    4
    Buy
    11
    Hold
    2
    Sell
    1
    Strong Sell
    0

    CRL Bull Case vs Bear Case

    Bull case

    • CRL beat EPS estimates in 100.0% of its last 8 reported quarters.
    • 83.3% of CRL's analyst ratings are Buy or Strong Buy.

    Bear case

    • CRL's quarterly revenue changed -2.2% year over year.

    CRL Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    8.5%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $3.73

    CRL Earnings Date

    CRL reports Feb 16, 2027, after the close. The date is estimated.

    CRL Earnings Call

    The latest CRL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    CRL ETF Holders

    GNG tracks 35 ETFs that hold CRL. The largest weights:

    1. MarketDesk Focused U.S. Momentum ETF (FMTM), 3.52% of the fund
    2. Invesco S&P 500 Equal Weight Health Care ETF (RSPH), 1.72% of the fund
    3. iShares Biotechnology ETF (IBB), 1.18% of the fund
    4. abrdn Healthcare Investors (HQH), 0.68% of the fund
    5. Vanguard Windsor Fund Admiral Shares (VWNEX), 0.59% of the fund
    Open the ETF Stock Exposure tool for CRL

    See insider activity

    Frequently Asked Questions About CRL

    When does CRL report earnings?

    Charles River Laboratories (CRL) is expected to report earnings on Feb 16, 2027.

    Does CRL pay dividends?

    Charles River Laboratories (CRL) does not currently pay a regular dividend.

    What is CRL's P/E ratio?

    Charles River Laboratories has a price-to-earnings (P/E) ratio of 32.00.

    What is CRL's market cap?

    Charles River Laboratories (CRL) has a market capitalization of $15.00B with a current stock price of $337.97.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In